FDA, EMA Collaborate on Model for Developing Rare Pediatric Drugs

International Pharmaceutical Regulatory Monitor
A A
The FDA and the European Medicines Agency released a draft joint plan to support the development of pediatric treatments for Gaucher disease — an approach the agencies say can apply to rare diseases in general.

To View This Article:

Login

Subscribe To International Pharmaceutical Regulatory Monitor